⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106820 | 1.00 | — | — | |
| SCHEMBL566852 | 1.00 | — | — | |
| SCHEMBL105431 | 0.79 | — | — | |
| SCHEMBL276895 | 0.76 | — | — | |
| SCHEMBL9205115 | 0.74 | OPRM1 (0.50) | — | |
| SCHEMBL9211873 | 0.74 | OPRM1 (0.50) | — | |
| SCHEMBL9214274 | 0.74 | OPRM1 (0.50) | — | |
| SCHEMBL276601 | 0.74 | OPRM1 (0.50) | — | |
| SCHEMBL9209648 | 0.74 | OPRM1 (0.50) | — | |
| SCHEMBL11033619 | 0.74 | OPRM1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-10117873-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2016-08-11 | — | — | US | disclosed |
| US-9346806-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2016-05-24 | — | — | US | disclosed |
| EP-3000813-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9233962-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2324026-B1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140336175-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8765772-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120035193-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-8067426-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2324026-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | Smithkline Beecham Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010018133-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |